Medical examiner Dr. Steven Campman told 60 Minutes that more than two doses of naloxone, a life-saving drug that can reverse opioid overdoses, might be necessary to save the life of someone who has overdosed on fentanyl.
Reversing a fentanyl overdose with naloxone Read More »
Fentanyl, which is often hidden in counterfeit pills, is fueling the worst drug crisis in U.S. history. Last year the synthetic opioid killed more than 70,000 Americans.
Fentanyl fueling worst drug crisis in U.S. history, killing 70,000 a year | 60 Minutes Read More »
CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc. (“Cessation”), a clinical-stage biotechnology company advancing biologics that target substances of abuse, today announced the presentation of preliminary data from its Phase 1a first-in-human study of CSX-1004, an investigational monoclonal antibody for prophylaxis against fentanyl-related overdose.
Scientists have developed an antibody treatment that shows promise inblockingthe potentially deadly effects of fentanyl for nearly a month, raising hopes for a new tool to combat overdoses. Tests in animals found that the treatment could effectively block the effects of fentanyl, laying the groundwork for assessing whether the medication will prove effective in humans,
Could a monthly treatment prevent fentanyl overdoses? Scientists are working on it Read More »
The opioid crisis in the United States is primarily driven by the highly potent synthetic opioid fentanyl leading to >70,000 overdose deaths annually; thus, new therapies for fentanyl overdose are urgently needed. Here, we present the first clinic-ready, fully human monoclonal antibody CSX-1004 with picomolar affinity for fentanyl and related analogs. In mice CSX-1004 reverses
Investigation of monoclonal antibody CSX-1004 for fentanyl overdose Read More »
If approved, CSX-1004 would be the first FDA-approved therapy for prevention of fentanyl-related overdose– CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc. (“Cessation”), a clinical-stage biotechnology company advancing biologics that target substances of abuse, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CSX-1004, an investigational therapy for prevention of fentanyl-related
CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc. (“Cessation), a clinical-stage biotechnology company advancing biologics that target substances of abuse, today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health) to support development of a subcutaneous formulation of its anti-fentanyl mAb,
CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc., (“Cessation”) a clinical-stage biotechnology company advancing biologics that target substances of abuse, announced today that the U.S. Food and Drug Administration (FDA) has authorized the company to initiate a clinical trial in the U.S. for CSX-1004, a monoclonal antibody designed specifically to prevent fentanyl overdose.
As a Navy admiral, I helped lead one of the most powerful militaries in the world. Today, our nation is fighting an urgent war right here at home. The opioid crisis in America has now become a fentanyl crisis. A synthetic opioid that is at least 50 times more potent than morphine, fentanyl is both exceedingly
Single administration of treatment blocked life-threatening, fentanyl-induced respiratory depression in non-human primates for at least 3 weeks CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics (“Cessation”), an early-stage biotechnology company focused on the development of novel immunobiologics for preventing and treating fentanyl overdose, today announced a new study demonstrating that its pioneering anti-fentanyl monoclonal antibody treatment, CSX-1004, may